We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

58 hedge funds and large institutions have $9.08M invested in Galectin Therapeutics in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 62 → 58 (-4)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

25% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 20

33% less capital invested

Capital invested by funds: $13.6M → $9.08M (-$4.56M)

97% less call options, than puts

Call options by funds: $7K | Put options by funds: $224K

Holders
58
Holders Change
-4
Holders Change %
-6.45%
% of All Funds
1.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
15
Reduced
20
Closed
15
Calls
$7K
Puts
$224K
Net Calls
-$217K
Net Calls Change
-$122K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$473K
2
US Bancorp
US Bancorp
Minnesota
+$274K
3
BCCM
Blue Clay Capital Management
Minnesota
+$225K
4
VKH
Virtu KCG Holdings
New York
+$202K
5
Millennium Management
Millennium Management
New York
+$143K

Top Sellers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
-$1.39M
2
SFM
Sphera Funds Management
Israel
-$739K
3
State Street
State Street
Massachusetts
-$581K
4
BIT
BlackRock Institutional Trust
California
-$348K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$155K
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
26
Paloma Partners
Connecticut
$81K +$90K +29,850 New
Morgan Stanley
27
Morgan Stanley
New York
$74K +$22.4K +7,422 +37%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$68K -$155K -51,279 -67%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$64K – – –
TCIM
30
TIAA CREF Investment Management
New York
$57K -$124K -41,239 -66%
Commonwealth Equity Services
31
Commonwealth Equity Services
Massachusetts
$57K -$10.9K -3,600 -15%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$57K +$32.4K +10,740 +105%
SGAM
33
Smith Group Asset Management
Texas
$50K +$4.59K +1,522 +9%
Bank of America
34
Bank of America
North Carolina
$48K -$244 -81 -0.5%
RG
35
Rathbones Group
United Kingdom
$45K – – –
RBC
36
Ronald Blue & Co
Georgia
$44K +$48.2K +16,000 New
AGM
37
Alpine Global Management
New York
$37K +$41.2K +13,681 New
State Street
38
State Street
Massachusetts
$33K -$581K -192,607 -94%
PPA
39
Parametric Portfolio Associates
Washington
$32K -$6.83K -2,265 -16%
SWP
40
Stratos Wealth Partners
Ohio
$30K -$24.1K -8,000 -42%
Citadel Advisors
41
Citadel Advisors
Florida
$29K +$32.5K +10,766 New
LP
42
LMR Partners
United Kingdom
$27K +$30.4K +10,099 New
GT
43
Glenmede Trust
Pennsylvania
$22K – – –
Wells Fargo
44
Wells Fargo
California
$20K +$7.5K +2,489 +52%
WAM
45
Wolverine Asset Management
Illinois
$18K +$20.2K +6,715 New
Deutsche Bank
46
Deutsche Bank
Germany
$9K +$2.61K +867 +33%
BIM
47
BlackRock Investment Management
Delaware
$8K -$154K -51,129 -94%
WP
48
WealthPLAN Partners
Nebraska
$7K – – –
UBS Group
49
UBS Group
Switzerland
$6K +$1.52K +504 +31%
First Manhattan
50
First Manhattan
New York
$4K – – –
1
2
3

GALT Hedge Fund Activity: Q2 2015 in Review

58 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2015, worth a combined $9.08M — down 33% from $13.6M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of GALT and 12 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 15 added.

The largest buyer was Susquehanna International Group, adding an estimated $473K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.39M.

  • 58 institutional investors held Galectin Therapeutics (GALT) as of Q2 2015, down from 62 in Q1 2015.
  • Funds reported $9.08M of Galectin Therapeutics stock for Q2 2015, down 33% quarter-over-quarter.
  • 12 funds opened new Galectin Therapeutics positions in Q2 2015 and 15 closed out, a net change of -3 holders.
  • The largest Galectin Therapeutics buyer in Q2 2015 was Susquehanna International Group, an estimated $473K added.
  • The largest Galectin Therapeutics seller in Q2 2015 was BlackRock Fund Advisors, an estimated $1.39M sold.

Based on aggregated 13F filings for Q2 2015.